Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
323U66 SR in Major Depressive Disorder
NCT00135512Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Primary completion
- May 2007
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bupropion in major depressive disorder (MDD), sponsored by GSK. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Dec 2004; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00135512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135512.